Corti Due Diligence

Run due diligence on Corti: check compliance and get alerts when suppliers or ownership change.

Denmark · owned by Independent (Denmark) · corti.ai · 20 vendors

Corti is an AI platform for healthcare developers, providing clinical-grade APIs for speech-to-text transcription, medical coding (ICD-10 & CPT), and clinical documentation. The company's Symphony model is purpose-built for clinical language, trained on real patient interactions and validated against real outcomes. Corti serves over 100 million patients annually and is HIPAA, GDPR, SOC 2, and ISO 27001 compliant.

Resilience scores

Technology vendors

Services catalogue

1 service in catalogue across 1 category; runs on 20 sub-vendors.

Insights

Last updated 2026-09-13 · revision 2

20 direct vendors, 246 subvendors

Direct vendors by controlling owner country (sample)

Subvendors by controlling owner country (sample)

Compliance

16 in-scope frameworks identified; showing 3.

EU AI Act (source) — No public evidence

Evidence: https://corti.ai/safety, https://corti.ai, https://corti.ai/sovereign-cloud, https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32024R1689

NIS2 (source) — Evidence found

Evidence: https://corti.ai/safety, https://corti.ai, https://app.drata.com/trust/9cc6d701-0c38-11ee-865f-029d78a187d9, https://corti.ai/sovereign-cloud

ISO 42001 — Evidence found

Evidence: https://corti.ai/safety, https://corti.ai

Financials

Three-year financials

Financial Resilience Score: 6/10

Corti is a well-funded, growth-stage Danish healthcare AI company backed by top-tier venture investors including Prosus Ventures, Atomico, and EIFO. The November 2022 Series B of approximately USD 60 million, following a USD 27 million Series A in 2020 led by EQT Ventures, provides multi-year cash runway to support continued R&D and go-to-market investment. The company has built strong strategic assets including marquee customers (NHS, Microsoft, Dedalus, Ramsay Santé), broad regulatory certifications (HIPAA, GDPR, ISO 13485, ISO 27001, ISO 42001, SOC 2, EU AI Act readiness, NHS DTAC/DSPT, FedRAMP, CE marking), and a diversified product suite spanning speech-to-text, medical coding, text generation, and agentic frameworks. However, as a typical Series B SaaS company, Corti is very likely still loss-making with substantial cash burn, meaning ongoing financial health depends on continued VC funding or reaching profitability. The company faces intense competition from Microsoft/Nuance DAX, Abridge, Ambience Healthcare, Suki, Nabla, and DeepScribe, as well as commoditization risk from foundational-model providers. Customer concentration in large national health systems introduces procurement cycle and churn risks, while FX exposure (DKK reporting vs. USD/GBP/EUR revenue) and evolving EU AI Act / FDA / MDR compliance costs add further uncertainty. Detailed financials from the Danish CVR filings were not accessible in this session, limiting quantitative assessment.

Key strengths: USD ~60M Series B (Nov 2022) led by Prosus Ventures, Atomico, EIFO, USD ~27M Series A (2020) led by EQT Ventures, Marquee customers: NHS, Microsoft, Dedalus, Ramsay Santé, Region Hovedstaden, Broad regulatory/compliance moat (HIPAA, GDPR, ISO 13485/27001/42001, SOC 2, FedRAMP, CE), Diversified product suite (speech-to-text, coding, generation, agentic framework), Consumption-based credit pricing scales with usage, Over 1 million interactions per week processed

Risk factors: Likely still loss-making with typical growth-stage cash burn, Dependence on continued VC funding for runway, Intense competition from Microsoft/Nuance DAX, Abridge, Ambience, Suki, Nabla, DeepScribe, Commoditization risk from foundational-model providers offering medical ASR, Customer concentration in slow-moving national health systems, EU AI Act high-risk classification for clinical AI adds compliance cost, FX exposure: DKK reporting vs USD/GBP/EUR revenue

Revenue by geography

Revenue by product/service

Workforce by country

Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.

View the full interactive report